Exploring how TP53 affects lung cell changes related to pulmonary fibrosis
Official title: Determining the role of TP53 regulation in alveolar epithelial transitional cell state, and the contribution of alveolar epithelial transitional cell state to pulmonary fibrosis
Funded at Duke University · NIH-11141548 · Data updated 2026-11-12
This study is looking at how a protein called TP53 helps lung cells change when they get injured, which could help us understand and find new treatments for pulmonary fibrosis, a serious lung condition that affects breathing.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | March 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $41,779 |
| NIH project number | 5F31HL172360-02 |
| Project ID | NIH-11141548 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary fibrosis or those experiencing unexplained lung injury.
✕Less likely to help
Patients with other respiratory conditions that do not involve pulmonary fibrosis may not benefit from this research.
What this research studies
This research investigates the role of the TP53 protein in regulating the transition of alveolar epithelial cells, which are crucial for lung function. By examining how these cells change in response to injury and contribute to pulmonary fibrosis, the study aims to uncover the underlying mechanisms of this severe lung disease. The approach includes analyzing single-cell data from human lungs affected by fibrosis to identify key molecular pathways. Patients may benefit from insights that could lead to new treatment strategies for pulmonary fibrosis.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic targets for treating pulmonary fibrosis, potentially improving patient outcomes.
How similar studies have gone: Previous research has shown promising results in understanding cellular transitions in lung diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Morowitz, Jeremy — Duke University
- Study coordinator: Morowitz, Jeremy
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.